Abstract:BACKGROUND:The National Comprehensive Cancer Network's Rectal Cancer Guideline Panel recommends American Joint Committee of Cancer and College of American Pathologists (AJCC/CAP) tumor regression grading (TRG) system to evaluate pathologic response to neoadjuvant chemoradiotherapy for locally advanced rectal cancer (LARC). Yet, the clinical significance of the AJCC/CAP TRG system has not been fully defined. MATERIALS AND METHODS:This was a multicenter, retrospectively recruited, and prospectively maintained cohort study. Patients with LARC from one institution formed the discovery set, and cases from external independent institutions formed a validation set to verify the findings from discovery set. Overall survival (OS), disease-free survival (DFS), local recurrence-free survival (LRFS), and distant metastasis-free survival (DMFS) were assessed by Kaplan-Meier analysis, log-rank test, and Cox regression model. RESULTS:The discovery set (940 cases) found, and the validation set (2,156 cases) further confirmed, that inferior AJCC/CAP TRG categories were closely /ccorrelated with unfavorable survival (OS, DFS, LRFS, and DMFS) and higher risk of disease progression (death, accumulative relapse, local recurrence, and distant metastasis) (all p < .05). Significantly, pairwise comparison revealed that any two of four TRG categories had the distinguished survival and risk of disease progression. After propensity score matching, AJCC/CAP TRG0 category (pathological complete response) patients treated with or without adjuvant chemotherapy displayed similar survival of OS, DFS, LRFS, and DMFS (all p > .05). For AJCC/CAP TRG1-3 cases, adjuvant chemotherapy treatment significantly improved 3-year OS (90.2% vs. 84.6%, p < .001). Multivariate analysis demonstrated the AJCC/CAP TRG system was an independent prognostic surrogate. CONCLUSION:AJCC/CAP TRG system, an accurate prognostic surrogate, appears ideal for further strategizing adjuvant chemotherapy for LARC. IMPLICATIONS FOR PRACTICE:The National Comprehensive Cancer Network recommends the American Joint Committee of Cancer and College of American Pathologists (AJCC/CAP) tumor regression grading (TRG) four-category system to evaluate the pathologic response to neoadjuvant treatment for patients with locally advanced rectal cancer; however, the clinical significance of the AJCC/CAP TRG system has not yet been clearly addressed. This study found, for the first time, that any two of four AJCC/CAP TRG categories had the distinguished long-term survival outcome. Importantly, adjuvant chemotherapy may improve the 3-year overall survival for AJCC/CAP TRG1-3 category patients but not for AJCC/CAP TRG0 category patients. Thus, AJCC/CAP TRG system, an accurate surrogate of long-term survival outcome, is useful in guiding adjuvant chemotherapy management for rectal cancer.

Adjuvant Treatment May Benefit Patients With High-Risk Upper Rectal Cancer: A Nomogram And Recursive Partitioning Analysis Of 547 Patients

Feasibility Of Relatively Low Neoadjuvantradiation Doses For Locally Advanced Rectal Cancer: A Propensity Score-Matched Analysis

Neoadjuvant Radiotherapy Improves Overall Survival for T3/4N+M0 Rectal Cancer Patients: a Population-Based Study of 20300 Patients

Predictors and Risk Factors of Pathologic Complete Response Following Neoadjuvant Chemoradiotherapy for Rectal Cancer: A Population-Based Analysis

College of American Pathologists Tumor Regression Grading System for Long-Term Outcome in Patients with Locally Advanced Rectal Cancer.

Risk stratification of stage II rectal mucinous adenocarcinoma to predict the benefit of adjuvant chemotherapy following neoadjuvant chemoradiation and surgery

Association Between Adjuvant Chemotherapy and Outcome in Locally Advanced Rectal Cancer Patients with Pathologic Complete Response after Neoadjuvant Treatment and Surgery

The clinical relevance of adjuvant chemotherapy in locally advanced rectal cancer patients achieving near pathological complete response following neoadjuvant chemoradiotherapy: Insights from ypT stage

Possible Contribution of IMRT in Postoperative Radiochemotherapy for Rectal Cancer: Analysis on 1798 Patients by Prediction Model

Beneficiaries of radical surgery among clinical complete responders to neoadjuvant chemoradiotherapy in rectal cancer

Effects of neoadjuvant chemotherapy with or without intensity‐modulated radiotherapy for patients with rectal cancer

Association between adjuvant chemotherapy and survival in patients with rectal cancer and pathological complete response after neoadjuvant chemoradiotherapy and resection

Overall Survival Benefit in Rectal Cancer After Neoadjuvant Radiotherapy and Adjuvant Chemotherapy: A Propensity-Matched Population-Based Study

Role of postoperative radiotherapy in pT3N0 rectal cancer: A risk-stratification system based on population analyses.

Adjuvant therapy for T3N0 rectal cancer in the total mesorectal excision era- identification of the high risk patients

Long-term efficacy of preoperative chemoradiotherapy combined with total mesorectal excision for locally advanced rectal cancer: an analysis of 241 patients

A nomogram for predicting cancer specific survival (CSS) in patients with pathological T3N0M0 (pT3N0M0) rectal cancer.

MRI-defined High-Risk Rectal Cancer Patients: Outcome Comparison Between Neoadjuvant Chemoradiotherapy Plus TME and TME Plus Adjuvant Chemotherapy or TME Alone

Influence of High-Risk Pathological Factors and their Interaction on the Survival Benefit of Adjuvant Chemotherapy in Stage II Rectal Cancer: A Retrospective Study

Role of Adjuvant Chemotherapy After Curative Resection in Stage II and III Rectal Cancer

Prognostic Ability of the Neoadjuvant Rectal (NAR) Score in Long‐course Concurrent Chemoradiotherapy for Patients with Locally Advanced Rectal Cancer: a Retrospective Cohort Study